Search Results
Search results for "Structure Therapeutics"
Results found for "Structure Therapeutics"
- FAQ | Dr. GPCR Ecosystem
Each session explores mechanistic models, translational challenges, and real-world therapeutic implications
- Finance is Science too: How Numbers Keep the Lights On with Chuck DeWeese & Joe St. Germain | Dr. GPCR Ecosystem
Chuck stepped in to help structure the nonprofit’s financial framework , showcasing how specialized knowledge It's about structure, order, and breakthrough moments , not unlike the life of a researcher. help you set up and come back when you’re ready.’” – Chuck DeWeese Accounting for Grants: Buckets, Structure
- Tanishka S. Saraf | Dr. GPCR Ecosystem
Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes
- The Scientist's Compass: From Academia to Entrepreneurship with Dr. Dmitry Veprintsev | Dr. GPCR Ecosystem
Membrane Proteins and Receptors (COMPARE), University of Nottingham, where he provides leadership in structural group leader at the Paul Scherrer Institute and ETH ZĂĽrich in Switzerland, changing his attention to structural
- Dr. Jean-Philippe Pin | Dr. GPCR Ecosystem
biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic
- Graciela Pineyro: Resilience, Lab Life, and the Zoom Effect | Dr. GPCR Ecosystem
What emerges is a quiet argument that the structural shifts the pandemic forced — project planning in Experimental planning under uncertainty — Structuring projects into self-contained blocks so a lab can The lab restructured projects into discrete, self-contained units — each one designed so that if the The implicit argument threaded through the whole conversation: the structural shifts forced by the shutdown
- Timeline Strategy | Scaling Biotech Operations with Dr. GPCR
objectives ✅ Build internal systems and workflows that support scale ✅ Create investor-ready operating structures It is the nature of scientific possibility. 👉 The problem begins when ambition grows faster than structure
- YC-BioTech | Dr. GPCR Ecosystem
guides program momentum Focus resources where they’ll change outcomes No More Strategy Swirl I build structure up clear deliverables across internal and CRO teams Keep cross-functional teams moving with shared structure
- spatiotemporal-organization-of-gpcr-signaling | Dr. GPCR Ecosystem
how GPCRs signal from internal membranes such as endosomes and the Golgi, work with direct bearing on therapeutic
- Dr. Thomas P. Sakmar | Dr. GPCR Ecosystem
Tom initially focused on structure-activity relationships underlying spectral tuning and identified a micro-domains” and the “helix movement model of receptor activation” were confirmed later when crystal structures
- The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi | Dr. GPCR Ecosystem
She has advanced the use of computational methods to meet the challenges of designing therapeutics with
- GPCR Assay Strategy, Bias, and Translational Drug Discovery | Dr. GPCR Ecosystem
At Tectonic Therapeutic, his lab contributed to the discovery of the RXFP1 agonist TX45, and he led the Keeping GLP1 receptors at the membrane can shape the therapeutic profile Building on work from Stephen
- Dr. Andrew Tobin | Dr. GPCR Ecosystem
vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics
- Dr. Adriano Marchese | Dr. GPCR Ecosystem
The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic
- Dr. John Janetzko | Dr. GPCR Ecosystem
Daniel Kahne and Suzanne Walker studying the structure and function of the essential human enzyme, O-GlcNAc Over the course of my graduate work, I gained experience with structural mass spectrometry and protein position after the recording stops. • John will prioritize getting feedback from people outside his lab to structure
- Recombinant Antibodies for GPCRs: A Challenge to the Community | Dr. GPCR Ecosystem
GeneTex is offering free samples of the recombinant antibodies to GPCR researchers in exchange for structured for specificity screening when feasible Free samples available to GPCR researchers willing to give structured
- Dr. Stephen Ferguson | Dr. GPCR Ecosystem
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).
- Dr. Stephen Ferguson | Dr. GPCR Ecosystem
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).
- Eleonora Comeo: Fluorescent Ligands and the Pharmacology of Adenosine Receptors | Dr. GPCR Ecosystem
Over 40 crystal structures of the A2A receptor alone have been deposited in the Protein Data Bank. affinity measurements shift depending on the assay 27:09 Synthesizing fluorescent ligands - from crystal structures "In chemistry, it's like when you finally see the NMR of your structure without anything but your compound
- Terry Hebert: How Cellular Background and Localization Influence GPCR Function | Dr. GPCR Ecosystem
Terry Hebert is a Professor of Pharmacology and Therapeutics at McGill University. The goal is to test therapeutic strategies targeting the AT1R, alpha-adrenergic, and beta-adrenergic
- Dr. Alix A. J. Rouault | Dr. GPCR Ecosystem
that MRAP2 regulates the signaling of multiple G protein-coupled receptors (GPCRs) through different structural C-terminal tail is not a docking space for the arrestins, but rather a necessary modification leading to a structural
- Dr. Prasenjit Saha | Dr. GPCR Ecosystem
receptors would be a significant breakthrough in cardiovascular biology as they could be targeted for therapeutic
- Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor | Dr. GPCR Ecosystem
Current lines of work include isoform-selective HSP90 inhibition as a strategy for widening the opioid therapeutic This is not a quirk — it is the central clue the lab has built a therapeutic strategy around.
- Sam Hoare: Receptor Residence Time and GPCR Data Analysis | Dr. GPCR Ecosystem
company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics
- Pfleger: NanoBRET, Receptor Complexes, and the Translation of GPCR Pharmacology | Dr. GPCR Ecosystem
GPCR field, and serves as Deputy Director of the Australian Research Council Centre for Personalised Therapeutics Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics
- Kari Johnson: mGlu2, Addiction, and the Brain Circuits Alcohol Rewires | Dr. GPCR Ecosystem
modulate drug seeking, habit formation, and reward processing - and has been pursued as a potential therapeutic adolescent alcohol exposure disrupts mGlu2 function in the striatum in a way that might seem to close off therapeutic
- Silvio Gutkind: Building a Lab That Doesn't Shut Down | Dr. GPCR Ecosystem
He walks through the structure his team built: staggered schedules at 10–15% occupancy, written contracts A small language correction with structural weight. Dr.
- Dr. Lukas Grätz | Dr. GPCR Ecosystem
branched out to multiple areas of GPCR research such as sequence alignments, generic numbering systems, structure
- Gáspár Pándy-Szekeres | Dr. GPCR Ecosystem
branched out to multiple areas of GPCR research such as sequence alignments, generic numbering systems, structure
- Dr. Daniel Isom | Dr. GPCR Ecosystem
biophysicist, systems and synthetic biologist, technologist, heavy CRISPR user, protein sequence- and structure-based



























